Brief: KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema

Kalvista Pharmaceuticals

18/06/2024 11:45

June 18 (Reuters) - Kalvista Pharmaceuticals Inc
 KALV.O :
    * KALVISTA SUBMITS NEW DRUG APPLICATION TO FDA FOR
SEBETRALSTAT AS
FIRST ORAL ON-DEMAND TREATMENT FOR HEREDITARY ANGIOEDEMA
    * KALVISTA PHARMACEUTICALS INC: CURRENTLY ANTICIPATES
RECEIVING
NOTIFICATION FROM FDA ON STATUS OF SUBMISSION IN SEPTEMBER
    * KALVISTA PHARMACEUTICALS INC: INTENDS TO SUBMIT ADDITIONAL
MARKETING AUTHORIZATION APPLICATIONS TO OTHER GLOBAL HEALTH
AUTHORITIES THROUGHOUT 2024
    * KALVISTA PHARMACEUTICALS INC: PLANS TO COMMENCE A
PEDIATRIC
TRIAL (KONFIDENT-KID) IN Q3 2024

Source text for Eikon:  ID:nBw50W76Xa 
Further company coverage:  KALV.O 

 ((Reuters.Briefs@thomsonreuters.com;))